Extended Cost-Effectiveness Analyses of Cardiovascular Risk Factor Reduction Policies
Authors: David Watkins, Rachel Nugent, Stéphane Verguet
In recent years, improvements in prevention and treatment have led to marked reductions in age-standardized mortality rates from cardiovascular disease (CVD) in low- and middle-income countries (LMICs). Yet because of rapid population growth and aging in these countries, the number of fatal and non-fatal cases of CVD continues to rise (Roth and others 2015). This increase in the absolute burden of CVD is accompanied by an increased economic impact of CVD that includes financial risks related to accessing treatment.